European Pharmaceutical Review
JULY 5, 2023
The long-awaited PDA TR 43 report provides an approach to a quality decision-making process and represents best practices for the identification and classification of visual nonconformities for (empty) glass containers as pharmaceutical product packaging.
pharmaphorum
OCTOBER 22, 2020
Purdue filed for bankruptcy last year, after it proposed a separate $10 to $12 billion settlement package to resolve those lawsuits. It admitted to bribing two doctors to write more prescriptions of OxyContin as well as other drugs between June 2009 and March 2017. Image by Gerd Altmann from Pixabay.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
RX Note
JUNE 8, 2023
In the past, package inserts were not always reliable sources of information regarding medication safety during lactation. Notable exceptions are heparin and insulin which are too large to cross biological membranes. As a general rule, breastfeeding is considered acceptable when the relative infant dose is <10%.
pharmaphorum
APRIL 11, 2022
Garabedian and his team plan to support VivoSense, not just with their funding package but with their industry network and connectivity. “We He served as the President and CEO of Sarepta Therapeutics from 2011 to 2015 and led corporate strategy for Celgene from 2007 to 2010 ( see more on LinkedIn ). This brings us to VivoSense.
RX Note
OCTOBER 5, 2023
Such events may be related to professional practice and healthcare products, procedures and systems, including prescribing; order communication; product labelling, packaging and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.
RX Note
MAY 18, 2023
A double-masked conjunctival allergen challenge (CAC) study in 2007 found no significant difference in the mean itching scores between two drops of olopatadine 0.1% (Patanol) and one drop of olopatadine 0.2% (Pataday). The packaging of Systane Ultra now writes: discard any remaining solution SIX months after first opening.
European Pharmaceutical Review
DECEMBER 13, 2022
There is now global awareness of this issue and FDA issued a guidance note on the problem in 2007. Tamper‑evident packaging is also recommended to prevent adulteration or contamination of the excipient. Pharmacopoeia guidance on DEG and EG. 3 Furthermore, the European Commission (EC) stated that “up to 0.1% Ann Intern Med.
Expert insights. Personalized for you.
96 
Let's personalize your content